688276 百克生物
已收盘 09-30 15:00:01
资讯
新帖
简况
百克生物:重组人源抗呼吸道合胞病毒单克隆抗体注射液项目处于临床前研究阶段
证券日报 · 09-26
百克生物:重组人源抗呼吸道合胞病毒单克隆抗体注射液项目处于临床前研究阶段
每周股票复盘:百克生物(688276)取消监事会并修订章程
证券之星 · 09-20
每周股票复盘:百克生物(688276)取消监事会并修订章程
每周股票复盘:百克生物(688276)带状疱疹疫苗销售下滑致业绩承压
证券之星 · 09-13
每周股票复盘:百克生物(688276)带状疱疹疫苗销售下滑致业绩承压
每周股票复盘:百克生物(688276)H1净亏损7357万
证券之星 · 09-06
每周股票复盘:百克生物(688276)H1净亏损7357万
股市必读:百克生物(688276)9月2日披露最新机构调研信息
证券之星 · 09-02
股市必读:百克生物(688276)9月2日披露最新机构调研信息
百克生物:9月1日接受机构调研,开源证券、福建豪山资产管理有限公司等多家机构参与
证券之星 · 09-02
百克生物:9月1日接受机构调研,开源证券、福建豪山资产管理有限公司等多家机构参与
每周股票复盘:百克生物(688276)Q2净利下滑196.88%
证券之星 · 08-31
每周股票复盘:百克生物(688276)Q2净利下滑196.88%
百克生物(688276)2025年中报简析:净利润同比下降153.47%,三费占比上升明显
证券之星 · 08-30
百克生物(688276)2025年中报简析:净利润同比下降153.47%,三费占比上升明显
图解百克生物中报:第二季度单季净利润同比下降196.88%
证券之星 · 08-29
图解百克生物中报:第二季度单季净利润同比下降196.88%
百克生物:2025年上半年净利润亏损7357.34万元
金融界 · 08-29
百克生物:2025年上半年净利润亏损7357.34万元
百克生物:鼻喷流感减毒活疫苗获批准
金融界 · 08-25
百克生物:鼻喷流感减毒活疫苗获批准
百克生物新注册《项目管理进度管理系统V1.0》项目的软件著作权
证券之星 · 08-19
百克生物新注册《项目管理进度管理系统V1.0》项目的软件著作权
百克生物:传信生物TMT101疫苗尚处临床前研究阶段
证券之星 · 08-15
百克生物:传信生物TMT101疫苗尚处临床前研究阶段
百克生物:产品出口至印度印尼等10余国
证券之星 · 08-15
百克生物:产品出口至印度印尼等10余国
8月15日百克生物涨8.09%,金鹰鑫瑞混合A基金重仓该股
证券之星 · 08-15
8月15日百克生物涨8.09%,金鹰鑫瑞混合A基金重仓该股
百克生物:在研管线目前暂无艾滋病疫苗
格隆汇 · 08-08
百克生物:在研管线目前暂无艾滋病疫苗
百克生物:深耕带状疱疹疫苗销售赛道
证券之星 · 08-08
百克生物:深耕带状疱疹疫苗销售赛道
百克生物:阿尔茨海默病治疗性疫苗现处于临床前研究阶段
证券之星 · 08-08
百克生物:阿尔茨海默病治疗性疫苗现处于临床前研究阶段
生物制品行业点评报告-减重赛道全球前沿进展跟踪(一):AMYLIN布局正当时
开源证券 · 08-03
生物制品行业点评报告-减重赛道全球前沿进展跟踪(一):AMYLIN布局正当时
百克生物中标昭觉县疫苗采购项目 券商看好公司长期发展
自选股中标信息 · 07-31
百克生物中标昭觉县疫苗采购项目 券商看好公司长期发展
加载更多
公司概况
公司名称:
长春百克生物科技股份公司
所属行业:
医药制造业
上市日期:
2021-06-25
主营业务:
长春百克生物科技股份公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗等。公司被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被吉林省工信厅认定为“省级企业技术中心”。
发行价格:
36.35
{"stockData":{"symbol":"688276","market":"SH","secType":"STK","nameCN":"百克生物","latestPrice":21.92,"timestamp":1759215601000,"preClose":21.9,"halted":0,"volume":1405568,"delay":0,"changeRate":0.0009,"floatShares":413999999,"shares":413999999,"eps":0.0506,"marketStatus":"已收盘","change":0.02,"latestTime":"09-30 15:00:01","open":21.89,"high":22.13,"low":21.77,"amount":30915100,"amplitude":0.0164,"askPrice":21.93,"askSize":25,"bidPrice":21.92,"bidSize":191,"shortable":0,"etf":0,"ttmEps":0.0506,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1759973400000},"marketStatusCode":5,"adr":0,"adjPreClose":21.9,"symbolType":"stock_kcb","openAndCloseTimeList":[[1759195800000,1759203000000],[1759208400000,1759215600000]],"highLimit":24.09,"lowLimit":19.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":413657598,"isCdr":false,"pbRate":2.23,"roa":"--","peRate":433.201581,"roe":"--","epsLYR":0.56,"committee":0.45351,"marketValue":9067000000,"turnoverRate":0.0034,"status":0,"afterMarket":{"amount":0,"volume":0,"close":21.92,"buyVolume":0,"sellVolume":0,"time":1759217637768,"indexStatus":"已收盘 09-30 15:30:00","preClose":21.9},"floatMarketCap":9067000000},"requestUrl":"/m/hq/s/688276","defaultTab":"news","newsList":[{"id":"2570861648","title":"百克生物:重组人源抗呼吸道合胞病毒单克隆抗体注射液项目处于临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2570861648","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570861648?lang=zh_cn&edition=full","pubTime":"2025-09-26 20:09","pubTimestamp":1758888540,"startTime":"0","endTime":"0","summary":"证券日报网讯百克生物9月26日在互动平台回答投资者提问时表示,公司在研项目中包含重组人源抗呼吸道合胞病毒单克隆抗体注射液项目,目前处于临床前研究阶段。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-26/doc-infrvstk0471178.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-26/doc-infrvstk0471178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2569246456","title":"每周股票复盘:百克生物(688276)取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2569246456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569246456?lang=zh_cn&edition=full","pubTime":"2025-09-21 04:38","pubTimestamp":1758400692,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,百克生物报收于22.05元,较上周的22.93元下跌3.84%。本周关注点公司公告汇总:百克生物股东大会通过取消监事会、修订公司章程的议案。长春百克生物科技股份公司于2025年9月16日召开2025年第二次临时股东会,会议审议通过上述两项议案。长春百克生物科技股份公司于2025年9月16日召开职工代表大会,选举孙晚丰先生为公司第六届董事会职工代表董事,任期至第六届董事会任期届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2567367661","title":"每周股票复盘:百克生物(688276)带状疱疹疫苗销售下滑致业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2567367661","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567367661?lang=zh_cn&edition=full","pubTime":"2025-09-14 05:19","pubTimestamp":1757798354,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘,百克生物报收于22.93元,较上周的22.98元下跌0.22%。机构调研要点2025年上半年,我国疫苗行业面临多方面挑战,肺炎疫苗、带状疱疹疫苗、流感疫苗等多款非免疫规划疫苗批签发批次同比下降,部分产品下降超50%。受外部环境、市场竞争加剧及接种意愿下降等因素影响,公司带状疱疹疫苗销售与使用数量大幅减少,销售收入承压,导致整体营业收入与净利润同比下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688276"],"gpt_icon":0},{"id":"2565548081","title":"每周股票复盘:百克生物(688276)H1净亏损7357万","url":"https://stock-news.laohu8.com/highlight/detail?id=2565548081","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565548081?lang=zh_cn&edition=full","pubTime":"2025-09-07 04:19","pubTimestamp":1757189950,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘,百克生物报收于22.98元,较上周的23.9元下跌3.85%。本周关注点业绩披露要点:2025年上半年公司净亏损7,357.34万元,同比下滑153.47%。带状疱疹疫苗全国城市覆盖率约98%,区县覆盖率约86%,安全库存合理;截至6月30日,全国近600家医院实现新准入。公司下半年将保持水痘疫苗领先地位,深耕带状疱疹疫苗与流感疫苗销售,推动医防融合新模式;液体鼻喷流感疫苗预计年底获批签发,争取实现销售;研发工作聚焦临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2564356633","title":"股市必读:百克生物(688276)9月2日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2564356633","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564356633?lang=zh_cn&edition=full","pubTime":"2025-09-03 05:20","pubTimestamp":1756848030,"startTime":"0","endTime":"0","summary":"截至2025年9月2日收盘,百克生物报收于23.17元,下跌1.82%,换手率1.11%,成交量4.6万手,成交额1.07亿元。来自机构调研要点:HSV-2 mRN疫苗预计下半年在北京开展临床研究。产品收入方面,水痘疫苗国内销售同比小幅下降,主要系出生率下降及市场竞争加剧,水痘疫苗厂家由五家增加到六家。公司带状疱疹疫苗目前在全国城市整体覆盖率约为98%,区县覆盖率约为86%,公司会保证合理的安全库存。截至6月30日,全国已有近600家医院实现了新的准入和突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300003447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2564805817","title":"百克生物:9月1日接受机构调研,开源证券、福建豪山资产管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2564805817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564805817?lang=zh_cn&edition=full","pubTime":"2025-09-02 18:04","pubTimestamp":1756807442,"startTime":"0","endTime":"0","summary":"产品收入方面,水痘疫苗国内销售同比小幅下降,主要系出生率下降及市场竞争加剧,水痘疫苗厂家由五家增加到六家。公司带状疱疹疫苗目前在全国城市整体覆盖率约为98%,区县覆盖率约为86%,公司会保证合理的安全库存。下半年,公司在保持水痘疫苗领先地位的同时,深耕带状疱疹疫苗以及流感疫苗销售赛道,基于产品特性、市场环境变化及医防协同政策导向,持续采取创新营销渠道策略,积极探索医防融合新模式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200030074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK1229","BK1258","09983","161027","BK0239","BK1583","BK1542"],"gpt_icon":0},{"id":"2563839843","title":"每周股票复盘:百克生物(688276)Q2净利下滑196.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563839843","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563839843?lang=zh_cn&edition=full","pubTime":"2025-08-31 11:08","pubTimestamp":1756609693,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘,百克生物报收于23.9元,较上周的24.77元下跌3.51%。本周,百克生物8月26日盘中最高价报25.72元。本周关注点来自业绩披露要点:2025年第二季度归母净利润为-7463.77万元,同比下降196.88%。股本股东变化截至2025年6月30日,百克生物股东户数为1.01万户,较3月31日增加40.0户,增幅0.4%。该议案拟取消监事会与监事设置,相关职权由董事会审计委员会行使,尚需提交股东会审议。公司发布《股权激励管理办法》,旨在建立激励与约束机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100003205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2563880440","title":"百克生物(688276)2025年中报简析:净利润同比下降153.47%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2563880440","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563880440?lang=zh_cn&edition=full","pubTime":"2025-08-31 06:17","pubTimestamp":1756592228,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期百克生物发布2025年中报。截至本报告期末,公司营业总收入2.85亿元,同比下降53.93%,归母净利润-7357.34万元,同比下降153.47%。本报告期百克生物三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达65.76%。去年的净利率为18.88%,算上全部成本后,公司产品或服务的附加值高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100001616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"gpt_icon":0},{"id":"2563004607","title":"图解百克生物中报:第二季度单季净利润同比下降196.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563004607","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563004607?lang=zh_cn&edition=full","pubTime":"2025-08-29 18:04","pubTimestamp":1756461863,"startTime":"0","endTime":"0","summary":"证券之星消息,百克生物2025年中报显示,公司主营收入2.85亿元,同比下降53.93%;归母净利润-7357.34万元,同比下降153.47%;扣非净利润-8223.24万元,同比下降160.78%;其中2025年第二季度,公司单季度主营收入1.23亿元,同比下降64.78%;单季度归母净利润-7463.77万元,同比下降196.88%;单季度扣非净利润-7882.04万元,同比下降204.4%;负债率22.67%,投资收益-1529.73万元,财务费用47.11万元,毛利率78.37%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900034778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"gpt_icon":0},{"id":"2563142320","title":"百克生物:2025年上半年净利润亏损7357.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2563142320","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563142320?lang=zh_cn&edition=full","pubTime":"2025-08-29 15:51","pubTimestamp":1756453894,"startTime":"0","endTime":"0","summary":"百克生物公告,2025年上半年营业收入2.85亿元,同比下降53.93%。净利润亏损7357.34万元,上年同期净利润1.38亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/29155152801918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688276"],"gpt_icon":0},{"id":"2562219895","title":"百克生物:鼻喷流感减毒活疫苗获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2562219895","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562219895?lang=zh_cn&edition=full","pubTime":"2025-08-25 15:39","pubTimestamp":1756107566,"startTime":"0","endTime":"0","summary":"百克生物公告,公司近日收到国家药品监督管理局下发的鼻喷流感减毒活疫苗《药品注册证书》。该疫苗适用于3(36月龄)至17岁人群,通过鼻腔接种方式在呼吸道形成预防流感病毒入侵的第一道免疫屏障。疫苗剂型由原冻干剂型升级为液体剂型,使用更便利。此次获批将有利于公司流感疫苗的推广和使用,优化产品结构,增强核心竞争力。但需注意,疫苗上市销售时间具有不确定性,存在投资风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25153952664370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2560116773","title":"百克生物新注册《项目管理进度管理系统V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2560116773","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560116773?lang=zh_cn&edition=full","pubTime":"2025-08-20 01:49","pubTimestamp":1755625754,"startTime":"0","endTime":"0","summary":"证券之星消息,近日百克生物(688276)新注册了《项目管理进度管理系统V1.0》项目的软件著作权。今年以来百克生物新注册软件著作权1个。结合公司2024年年报财务数据,2024年公司在研发方面投入了1.56亿元,同比减21.17%。通过天眼查大数据分析,长春百克生物科技股份公司共对外投资了7家企业,参与招投标项目1036次;财产线索方面有商标信息44条,专利信息69条,著作权信息3条;此外企业还拥有行政许可133个。数据来源:天眼查APP以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082000000742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2559918124","title":"百克生物:传信生物TMT101疫苗尚处临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2559918124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559918124?lang=zh_cn&edition=full","pubTime":"2025-08-15 16:51","pubTimestamp":1755247869,"startTime":"0","endTime":"0","summary":"参股公司传信生物医药(苏州)有限公司自主研发的“新型mRNA肿瘤疫苗TMT101”一期临床试验效果如何百克生物回复:尊敬的投资者您好,传信生物自主研发的“新型mRNA肿瘤疫苗TMT101”尚处于临床前研究阶段,目前在北京协和医院开展了一项“研究者发起的临床试验”,该研究是由北京协和医院发起,用于评估TMT101在晚期胰腺癌或非小细胞肺癌患者中的安全性、耐受性和有效性,感谢您的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500031697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688276"],"gpt_icon":0},{"id":"2559918675","title":"百克生物:产品出口至印度印尼等10余国","url":"https://stock-news.laohu8.com/highlight/detail?id=2559918675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559918675?lang=zh_cn&edition=full","pubTime":"2025-08-15 16:45","pubTimestamp":1755247531,"startTime":"0","endTime":"0","summary":"证券之星消息,百克生物(688276)08月15日在投资者关系平台上答复投资者关心的问题。投资者提问:公司哪些产品出口国外,年收益怎么样百克生物回复:尊敬的投资者您好,公司产品已出口至印度、印度尼西亚等10余个国家,并积极推进国际市场的拓展。2024年公司带状疱疹疫苗首次出口至哥伦比亚;水痘疫苗首次出口至阿富汗。具体经营数据请关注公司定期报告,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500031524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239","MNDmain"],"gpt_icon":0},{"id":"2559209990","title":"8月15日百克生物涨8.09%,金鹰鑫瑞混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2559209990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559209990?lang=zh_cn&edition=full","pubTime":"2025-08-15 16:27","pubTimestamp":1755246424,"startTime":"0","endTime":"0","summary":"证券之星消息,8月15日百克生物涨8.09%创60日新高,收盘报25.4元,换手率2.7%,成交量11.19万手,成交额2.75亿元。重仓百克生物的公募基金请见下表:根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为金鹰基金的金鹰鑫瑞混合A。金鹰鑫瑞混合A目前规模为2.48亿元,最新净值1.3016,较上一交易日下跌0.15%,近一年上涨4.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500030904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2557542305","title":"百克生物:在研管线目前暂无艾滋病疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2557542305","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557542305?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:39","pubTimestamp":1754642354,"startTime":"0","endTime":"0","summary":"格隆汇8月8日丨百克生物(688276.SH)在投资者互动平台表示,公司在研管线目前暂无艾滋病疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808164510a47cd7f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808164510a47cd7f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688276","BK0239","159646"],"gpt_icon":0},{"id":"2557490455","title":"百克生物:深耕带状疱疹疫苗销售赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2557490455","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557490455?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:27","pubTimestamp":1754641648,"startTime":"0","endTime":"0","summary":"投资者提问:带状疱疹疫苗已获21批签发证明,面对GSK等竞品,公司如何制定差异化销售策略?百克生物回复:尊敬的投资者您好,公司带状疱疹疫苗本年度批签发2批,具体批签发信息请关注中国食品药品检定研究院以及吉林省药品检定研究院的相关公示信息。市场营销方面,公司深耕带状疱疹疫苗销售赛道,采取科普宣传、学术交流、品牌营销等多种方式拓展市场,着力提升受众者疾病认知和防病意识,提升产品品牌认知度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800025609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688276"],"gpt_icon":0},{"id":"2557490235","title":"百克生物:阿尔茨海默病治疗性疫苗现处于临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2557490235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557490235?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:27","pubTimestamp":1754641647,"startTime":"0","endTime":"0","summary":"证券之星消息,百克生物(688276)08月08日在投资者关系平台上答复投资者关心的问题。投资者提问:阿尔茨海默病治疗性疫苗的临床进展是否顺利?百克生物回复:尊敬的投资者您好,公司阿尔茨海默病治疗性疫苗现处于临床前研究阶段,公司将积极推进该项目研发进展,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800025608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688276"],"gpt_icon":0},{"id":"2556879631","title":"生物制品行业点评报告-减重赛道全球前沿进展跟踪(一):AMYLIN布局正当时","url":"https://stock-news.laohu8.com/highlight/detail?id=2556879631","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556879631?lang=zh_cn&edition=full","pubTime":"2025-08-04 00:00","pubTimestamp":1754236800,"startTime":"0","endTime":"0","summary":"近期重磅BD 交易总结艾伯维和罗氏先后在2025 年一季度花重金布局amylin 分子。艾伯维将支付首付款3.5 亿美金,里程碑高达18.75 亿美金,以及销售分成。高质量减重方面,临床前DIO 大鼠数据显示Eloralintide 减少的体重最高达91%为脂肪。而目前GLP-1 类药物减重中约20%-40%为瘦体重。此外,礼来在ADA 大会上表示未来不排除eloralintide 开发月度制剂的可能性。Metsera 公司明确MET-223i 将定位为月度制剂。值得指出的是,Structure 和众生药业以小分子形式切入了amylin 赛道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688739","603590","603392","688163","688166","688443","600739","688488","600211","688520","BK0239","688687","688319","600161","688670","688105","600867","688293","688137","688177","688276","688278","688336","603087"],"gpt_icon":0},{"id":"2555887187","title":"百克生物中标昭觉县疫苗采购项目 券商看好公司长期发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2555887187","media":"自选股中标信息","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555887187?lang=zh_cn&edition=full","pubTime":"2025-07-31 18:59","pubTimestamp":1753959565,"startTime":"0","endTime":"0","summary":"2025年07月31日,据天眼查数据,四川省凉山彝族自治州昭觉县疾病预防控制中心关于昭觉县2025年非免疫规划疫苗采购遴选结果公示显示,中标方为百克生物,招标方为四川省凉山彝族自治州昭觉县疾病预防控制中心。近半年内,百克生物获得1家券商积极评价:国投证券给予\"买入\"评级。百克生物主营业务涵盖水痘疫苗,带状疱疹疫苗,鼻喷流感疫苗。截至发稿,百克生物股价报23.36元,下跌1.14%,成交额至9985.43万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731185927a46d6eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731185927a46d6eaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688276","BK0239","159646"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1759970271485,"stockEarnings":[{"period":"1week","weight":0.0219},{"period":"1month","weight":-0.0828},{"period":"3month","weight":0.0438},{"period":"6month","weight":-0.0817},{"period":"1year","weight":-0.2779},{"period":"ytd","weight":-0.1201}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0064},{"period":"3month","weight":0.1239},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.1637},{"period":"ytd","weight":0.1584}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春百克生物科技股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10094人(较上一季度增加0.40%)","perCapita":"40980股","listingDate":"2021-06-25","address":"吉林省长春市朝阳区高新开发区火炬路1260号","registeredCapital":"41365万元","survey":" 长春百克生物科技股份公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗等。公司被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被吉林省工信厅认定为“省级企业技术中心”。","listedPrice":36.35},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百克生物,688276,百克生物股票,百克生物股票老虎,百克生物股票老虎国际,百克生物行情,百克生物股票行情,百克生物股价,百克生物股市,百克生物股票价格,百克生物股票交易,百克生物股票购买,百克生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}